A Randomized Phase II Trial of Cabozantinib Combined With PD-1 and CTLA-4 Inhibition in Metastatic Soft Tissue Sarcoma
Latest Information Update: 13 Jun 2024
At a glance
- Drugs Cabozantinib (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Soft tissue sarcoma
- Focus Therapeutic Use
- 07 Jun 2024 Planned End Date changed from 1 Jun 2029 to 1 Jun 2030.
- 07 Jun 2024 Planned primary completion date changed from 1 Jun 2024 to 1 Jun 2025.
- 17 Mar 2024 Planned End Date changed from 31 Aug 2028 to 1 Jun 2029.